A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...

Among men with abnormal levels by any criterion (except PSA velocity), 40% to 55% of those who did not develop documented prostate cancer in the interim exhibited subsequent normal values. The authors ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

A new test could be more effective at detecting dangerous prostate cancer than current screening methods, a study suggests.

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic ...

There is a general consensus among clinicians that a serum prostate-specific antigen (PSA) level ≥4.0 ng/ml is predictive of prostate cancer, and necessitates a biopsy. But there is a dearth of ...

The understanding of prostate cancer has significantly evolved in the past 15 years. However, many people—including primary care providers—may not be aware of the current guidelines for prostate ...

February 10, 2023 – Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with ...